What is Thymosin-α1?

Thymosin-α1 is a research peptide in the Healing & Recovery class. 28-aa immunomodulator; upregulates T-cell maturation. It is studied at per-dose ranges of 1.6 mg × 2 / week (3.2 mg weekly), administered twice-weekly sc over cycles of 4–8 weeks. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

Thymus-derived peptide. Registered in >30 countries for hepatitis B and adjuvant oncology use.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does Thymosin-α1 work?

Primary mechanism: 28-aa immunomodulator; upregulates T-cell maturation. Research on Thymosin-α1 implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for Thymosin-α1 remain areas of active investigation; several proposed effects within the Healing & Recovery class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

Thymosin-α1 dosage & protocol

Reference protocol for Thymosin-α1 (research context only, drawn from published literature):

  • Per dose: 1.6 mg × 2 / week
  • Weekly total: 3.2 mg
  • Frequency: Twice-weekly SC
  • Cycle: 4–8 weeks

Stacking Thymosin-α1

Commonly referenced pairing with Thymosin-α1: Monotherapy. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a Thymosin-α1 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Immunosuppressive therapy. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Thymosin-α1 — common questions

What is Thymosin-α1 and what is it used for in research?
Thymosin-α1 is classified within the Healing & Recovery group. Thymus-derived peptide. Registered in >30 countries for hepatitis B and adjuvant oncology use. Research applications focus on the pathways outlined below. All references on this page describe published research only — Thymosin-α1 is supplied for in-vitro and laboratory use, not for human consumption.
How does Thymosin-α1 work?
Primary mechanism: 28-aa immunomodulator; upregulates T-cell maturation. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for Thymosin-α1 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical Thymosin-α1 research dose?
Published research protocols for Thymosin-α1 describe per-dose ranges of 1.6 mg × 2 / week, with a weekly total near 3.2 mg, administered twice-weekly sc. Typical cycle: 4–8 weeks. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy Thymosin-α1 in Thailand?
Thymosin-α1 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can Thymosin-α1 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016. PMID: 27450734

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.